[go: up one dir, main page]

AU6753194A - Use of N-(pyridinyl)-1H-indole-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders - Google Patents

Use of N-(pyridinyl)-1H-indole-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders

Info

Publication number
AU6753194A
AU6753194A AU67531/94A AU6753194A AU6753194A AU 6753194 A AU6753194 A AU 6753194A AU 67531/94 A AU67531/94 A AU 67531/94A AU 6753194 A AU6753194 A AU 6753194A AU 6753194 A AU6753194 A AU 6753194A
Authority
AU
Australia
Prior art keywords
preparation
treatment
obsessive
pyridinyl
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU67531/94A
Other versions
AU673747B2 (en
Inventor
Sathapana Kongsamut
Craig Paul Smith
Ann Theresa Woods
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventisub LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventisub LLC filed Critical Aventisub LLC
Publication of AU6753194A publication Critical patent/AU6753194A/en
Assigned to HOECHST MARION ROUSSEL, INC. reassignment HOECHST MARION ROUSSEL, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED
Application granted granted Critical
Publication of AU673747B2 publication Critical patent/AU673747B2/en
Assigned to AVENTIS PHARMACEUTICALS INC. reassignment AVENTIS PHARMACEUTICALS INC. Request to Amend Deed and Register Assignors: HOECHST MARION ROUSSEL, INC.
Assigned to AVENTIS HOLDINGS INC. reassignment AVENTIS HOLDINGS INC. Alteration of Name(s) in Register under S187 Assignors: AVENTIS PHARMACEUTICALS INC.
Assigned to AVENTISUB II INC. reassignment AVENTISUB II INC. Alteration of Name(s) in Register under S187 Assignors: AVENTIS HOLDINGS INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of a compound of formula I,where   m is 0, 1 or 2;   R is halogen, loweralkyl, loweralkoxy, arylloweralkoxy, hydroxy, nitro, amino, loweralkylamino or diloweralkylamino;   R₁ is H or loweralkyl;   R₂ is H or loweralkyl; and   R₃ is H, halogen or loweralkyl, or a pharmaceutically acceptable and addition salt thereof, for the preparation of medicaments, for the treatment of obsessive compulsive disorders.
AU67531/94A 1993-07-19 1994-07-15 Use of N-(pyridinyl)-1H-indole-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders Expired AU673747B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US092848 1987-08-24
US08/092,848 US5356910A (en) 1993-07-19 1993-07-19 Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder

Publications (2)

Publication Number Publication Date
AU6753194A true AU6753194A (en) 1995-01-27
AU673747B2 AU673747B2 (en) 1996-11-21

Family

ID=22235450

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67531/94A Expired AU673747B2 (en) 1993-07-19 1994-07-15 Use of N-(pyridinyl)-1H-indole-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders

Country Status (21)

Country Link
US (1) US5356910A (en)
EP (1) EP0635269B1 (en)
JP (1) JP2807633B2 (en)
KR (1) KR100325276B1 (en)
AT (1) ATE186215T1 (en)
AU (1) AU673747B2 (en)
CA (1) CA2128312C (en)
CZ (1) CZ288593B6 (en)
DE (1) DE69421457T2 (en)
DK (1) DK0635269T3 (en)
EG (1) EG20716A (en)
ES (1) ES2138017T3 (en)
GR (1) GR3032292T3 (en)
HU (1) HU217063B (en)
MX (1) MX9405209A (en)
NO (1) NO306597B1 (en)
NZ (1) NZ264015A (en)
PL (1) PL304335A1 (en)
RU (1) RU2164795C2 (en)
TW (1) TW349864B (en)
ZA (1) ZA945236B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
ATE218343T1 (en) * 1995-07-27 2002-06-15 Aventis Pharma Inc USE OF SUBSTITUTED AND UNSUBSTITUTED N-(PYRROL-1-YL)PYRIDINAMINES AS ANTICONVULSIVES
HUP9802413A3 (en) * 1995-07-27 2002-02-28 Aventis Pharmaceuticals Inc Br Use of n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents and for the preparation of a pharmaceutical composition for the treatment of convulsions
JP4608723B2 (en) * 1999-03-10 2011-01-12 東ソー株式会社 Method for producing substituted indole derivatives
GT200500063A (en) * 2004-04-01 2005-10-14 METHOD FOR TREATMENT OF SCHIZOPHRENIA AND / OR GLUCOREGULATORY ABNORMALITIES
FR2892021B1 (en) * 2005-10-19 2008-01-04 Urogene TREATMENT OF URINARY INCONTINENCE OF EFFORT AND MIXED
FR2892022B1 (en) * 2005-10-19 2008-01-04 Urogene Sa TREATMENT OF SYMPTOMS OF BLADDER IRRITATION
FR2897614B1 (en) * 2006-02-20 2008-05-23 Urogene CRYSTALLINE FORM OF BESIPIRDINE HYDROCHLORIDE, METHODS OF PREPARATION AND USES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115143T1 (en) 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(PYRIDINYL)-1H-INDOL-1-AMINES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS MEDICINES.
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US5179099A (en) * 1989-08-02 1993-01-12 Hoechst-Roussel Pharmaceuticals Incorporated 2,3-dihydro-1-(pyridinylamino)-indoles
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5177088A (en) 1991-04-17 1993-01-05 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 3-(pyridinylamino)-indoles
US5185350A (en) 1991-09-23 1993-02-09 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1h-indoles,1h-indazoles,2h-indazoles, benzo (b)thiophenes and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
EG20716A (en) 1999-12-29
MX9405209A (en) 1995-01-31
RU94026084A (en) 1996-08-27
CA2128312A1 (en) 1995-01-20
KR100325276B1 (en) 2002-09-25
DK0635269T3 (en) 2000-04-25
EP0635269B1 (en) 1999-11-03
US5356910A (en) 1994-10-18
CZ173094A3 (en) 1995-02-15
NO306597B1 (en) 1999-11-29
PL304335A1 (en) 1995-01-23
NZ264015A (en) 1997-07-27
ES2138017T3 (en) 2000-01-01
ZA945236B (en) 1995-02-28
KR950002761A (en) 1995-02-16
DE69421457T2 (en) 2000-05-04
AU673747B2 (en) 1996-11-21
ATE186215T1 (en) 1999-11-15
EP0635269A1 (en) 1995-01-25
JPH0753376A (en) 1995-02-28
RU2164795C2 (en) 2001-04-10
DE69421457D1 (en) 1999-12-09
HU217063B (en) 1999-11-29
CA2128312C (en) 2004-09-28
HUT69709A (en) 1995-09-28
NO942695L (en) 1995-01-20
GR3032292T3 (en) 2000-04-27
TW349864B (en) 1999-01-11
NO942695D0 (en) 1994-07-18
HU9402124D0 (en) 1994-09-28
CZ288593B6 (en) 2001-07-11
JP2807633B2 (en) 1998-10-08

Similar Documents

Publication Publication Date Title
CA2216796A1 (en) Quinazoline derivatives
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
TR200000129T2 (en) Brand new spiroazabicyclic heterocyclic compounds.
PL314086A1 (en) Novel (r)-8-fluoro-3-n,n-substituted amino 3,4-dihydro 5-carbamoyl-2h-1-bezopyranes
AP9701041A0 (en) Pyridylpyrrole compounds.
AU5752194A (en) Benzimidazole compounds, their use and preparation
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
WO1997005862A3 (en) Use of basic amino acids and derivatives for lowering ceramide levels
WO1999012532A3 (en) Piperidine derivatives against malaria
RU94046141A (en) Substituted(arylalkoxybenzyl)aminopropaneamide derivatives, processes for preparation thereof, and pharmaceutical composition
AU6753194A (en) Use of N-(pyridinyl)-1H-indole-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
AU3955199A (en) Remedies for itching containing PGD2 antagonists
TW285640B (en)
SE9702716D0 (en) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
CA2120319A1 (en) Pharmaceutical for the treatment of skin disorders
CA2187402A1 (en) Quinoxaline Derivatives for Treating Tinnitus
WO1994016705A3 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: AVENTIS PHARMACEUTICALS INC.

Free format text: FORMER NAME WAS: HOECHST MARION ROUSSEL, INC.